Zacks.com on MSN29m
FDA Begins Review of Alnylam's sNDA for Expanded Amvuttra UseALNY reports submitting an sNDA in the United States, seeking the label expansion of Amvuttra to treat ATTR amyloidosis with cardiomyopathy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback